These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34868553)

  • 1. A signaling pathway-driven bioinformatics pipeline for predicting therapeutics against emerging infectious diseases.
    Scott TM; Jensen S; Pickett BE
    F1000Res; 2021; 10():330. PubMed ID: 34868553
    [No Abstract]   [Full Text] [Related]  

  • 2. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
    Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
    J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
    Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 infection mediates differential expression of human endogenous retroviruses and long interspersed nuclear elements.
    Marston JL; Greenig M; Singh M; Bendall ML; Duarte RRR; Feschotte C; Iñiguez LP; Nixon DF
    JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34731091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
    Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19.
    Halaji M; Farahani A; Ranjbar R; Heiat M; Dehkordi FS
    Infez Med; 2020 Jun; 28(suppl 1):6-17. PubMed ID: 32532933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.
    Abd El-Aziz TM; Stockand JD
    Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.
    Bchetnia M; Girard C; Duchaine C; Laprise C
    J Infect Public Health; 2020 Nov; 13(11):1601-1610. PubMed ID: 32778421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel zoonotic COVID-19 pandemic: An expected global health concern.
    Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
    J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Bioinformatics Pipelines for Enrichment Illumina Next Generation Sequencing Systems in Detecting SARS-CoV-2 Virus Strains.
    Afiahayati ; Bernard S; Gunadi ; Wibawa H; Hakim MS; Marcellus ; Parikesit AA; Dewa CK; Sakakibara Y
    Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 35893066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome.
    Ye C; Chiem K; Park JG; Oladunni F; Platt RN; Anderson T; Almazan F; de la Torre JC; Martinez-Sobrido L
    mBio; 2020 Sep; 11(5):. PubMed ID: 32978313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS.
    Fathi M; Vakili K; Deravi N; Yaghoobpoor S; Ahsan E; Mokhtari M; Moshfeghi M; Vaezjalali M
    Przegl Epidemiol; 2020; 74(2):276-289. PubMed ID: 33112124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
    Elfiky AA
    Life Sci; 2020 Jul; 253():117592. PubMed ID: 32222463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us.
    Kumar V
    Int Rev Immunol; 2021; 40(1-2):5-53. PubMed ID: 32744465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.